Holen Sie sich die Stockscreener-App
73.52
3.54%
-2.70
Handel nachbörslich:
74.99
1.47
+2.00%
Schlusskurs vom Vortag:
$76.22
Offen:
$74.91
24-Stunden-Volumen:
125.43K
Relative Volume:
0.74
Marktkapitalisierung:
$813.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.96%
1M Leistung:
+29.35%
6M Leistung:
+200.82%
1J Leistung:
+0.00%
1-Tages-Spanne:
$72.31
$75.74
1-Wochen-Bereich:
$65.93
$76.76
52-Wochen-Spanne:
$11.17
$76.76
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
125 STRAFFORD AVE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
73.52 | 773.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Is Palvella Therapeutics Inc. meeting your algorithmic filter criteriaNew Guidance & AI Driven Stock Movement Reports - newser.com
Can Palvella Therapeutics Inc. stock rebound after recent weaknessTrade Entry Summary & Community Verified Watchlist Alerts - newser.com
Trend analysis for Palvella Therapeutics Inc. this weekMarket Volume Report & Real-Time Chart Breakout Alerts - newser.com
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $75.50 Consensus PT from Analysts - Defense World
Can Palvella Therapeutics Inc. rally from current levelsWeekly Loss Report & Risk Managed Investment Strategies - newser.com
Can Palvella Therapeutics Inc. stock withstand economic slowdownBuy Signal & Accurate Entry/Exit Alerts - newser.com
Palvella Receives Second Year of FDA Grant Funding for Phase 3 Qtorin Trial - MarketScreener
What Fibonacci levels say about Palvella Therapeutics Inc. reboundWall Street Watch & Free Community Supported Trade Ideas - newser.com
U.S. FDA awards year two funds to Palvella's phase 3 Selva trial - MarketScreener
U.S. Food and Drug Administration Awards Year Two Proceeds - GlobeNewswire
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - Yahoo Finance
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 5.9%What's Next? - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Palvella Therapeutics Inc. reversing from oversold territoryJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Palvella Therapeutics' (PVLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Canaccord Genuity raises Palvella Therapeutics stock price target to $90 on new indication - Investing.com Canada
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Can trapped investors hope for a rebound in Palvella Therapeutics Inc.Quarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Swing Trade & Weekly Top Performers Watchlists - newser.com
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients - MSN
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 6.6% HigherHere's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighHere's Why - MarketBeat
Tick level data insight on Palvella Therapeutics Inc. volatilityMarket Rally & AI Driven Price Predictions - newser.com
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stock2025 Price Targets & Long-Term Capital Growth Strategies - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Earnings Overview Report & Safe Investment Capital Preservation Plans - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportTrade Analysis Summary & Detailed Earnings Play Alerts - newser.com
LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
Strid Group LLC Lowers Stake in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsWeekly Gains Summary & Step-by-Step Swing Trade Plans - newser.com
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $80 - 富途牛牛
Published on: 2025-10-03 02:03:51 - newser.com
Truist Securities Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $80.00 - MarketBeat
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MSN
Can Palvella Therapeutics Inc. (PI6) stock attract ESG investments2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - 富途牛牛
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment - MSN
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):